DexCom (NasdaqGS:DXCM) is upgrading its Stelo glucose monitoring platform with AI driven features that expand its nutrition database and deliver more personalized health insights. The new tools focus ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...
Investor's Business Daily on MSN
Could 2026 be Dexcom's 'get right' year? New CEO Jake Leach says yes.
For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...
DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc (DXCM). (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, ...
Zacks Investment Research on MSN
DexCom (DXCM) is a top-ranked growth stock: Should you buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results